August 18, 2017 5:41pm
As its outlook is murky, trends and patterns look opaque or just don’t exist
So, what is sector and market outlook?
… Continued pressure on share pricing!
Out and about; Biostage (BSTG) gets slammed again -$0.044 or -13.01% to a new bottom of $0.295 with 2.16 M shares traded. A far cry from Q1/15’s $4.43 and Q4/15’s $3.47 and Q1/16’s $2.60 and Q2’s $2.86 and Q4’s $1.42 … as January ‘17 started at $0.87 … great fiduciary performance – CEO McGorry!
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter, “this … markets has the jitters and the sector has the heebie-jeebies. Where is the sustainable value in cell therapy land again? Share pricing leadership has its issues … it slips, dips and uncertainty keeps it uncontrollable.”
- I also stated, “This may be the most drugged-up sector as the same old patterns keep repeating themselves!
Even as tensions heightened between the oversold and the overbought, the undervalued become more glaring or are they?
- The old issue of climbing that “wall of worry” seeds more and more predictions of even more selloffs …
How many ways can one say the same things …?
- The sector’s downside continues to rock its capacity to be sustainable – now to be flat in a down market is a gift!
A number of indicators point to a steady, halting deterioration of some of the factors that could cause steady deterioration of equities.
“The small-cap oriented Russell 2000 index RUT, -0.08% on Thursday fell below its widely-watched 200-d
